HWI group takes over the Frankfurt development site of Losan Pharma GmbH and hereby extends its range of services. HWI is thus further developing its strategy in the direction of high potent active ingredients and sterile dosage forms. State-of-the-art isolator technology makes it possible to process high potent substances safely. Another focus of the site will be the development of sterile drugs, that are subject to particularly high purity and quality requirements.
More information about drug development.